The clinical landscape of primary hyperparathyroidism (PHPT) has long been defined by a clear therapeutic gold standard: surgical intervention. However, a recent case study published in JCEM Case Reports by Sara Ramadan, MD, and her mentor Shirin Haddady, MD, MPH, has introduced a compelling anomaly into the medical literature. The study, titled “Unanticipated remission of primary hyperparathyroidism following cinacalcet,” documents the regression of a parathyroid adenoma and the subsequent long-term remission of the disease in a patient treated with medical therapy alone. This finding challenges the established understanding of cinacalcet’s role in PHPT management and opens new avenues for discussing the biological mechanisms of parathyroid tumor involution.
Primary hyperparathyroidism is a common endocrine disorder, ranking third in global prevalence behind diabetes mellitus and thyroid diseases. It affects approximately 1% of the adult population and is characterized by the overproduction of parathyroid hormone (PTH) from one or more of the four parathyroid glands. This overproduction leads to hypercalcemia, which can result in a range of complications, including osteoporosis, kidney stones, and cognitive impairment. While the majority of cases are caused by a single benign adenoma, the only definitive cure has traditionally been the surgical removal of the overactive tissue.
Clinical Presentation and Diagnostic Findings
The case centered on a 68-year-old male who was referred to the endocrine clinic at Boston Medical Center-Brighton following a routine laboratory screening. The patient’s initial biochemical profile was indicative of severe primary hyperparathyroidism. His serum calcium level was recorded at 12.1 mg/dL, significantly exceeding the typical upper limit of approximately 10.5 mg/dL. Concurrently, his intact parathyroid hormone (PTH) level was measured at 451 pg/mL, which is nearly seven times the upper reference limit of 65 pg/mL.
Further diagnostic testing revealed the systemic impact of the hormonal imbalance. The patient’s phosphate levels were low at 2.2 mg/dL, and a dual-energy X-ray absorptiometry (DEXA) scan confirmed the presence of osteopenia, particularly in the femoral neck, where the T-score was –2.0. To identify the source of the PTH overproduction, the medical team utilized high-resolution ultrasonography. The imaging revealed a well-demarcated, homogeneous, hypoechoic mass measuring 2.3 × 1.7 × 3.0 cm, located posterior to the inferior right thyroid lobe. The mass exhibited peripheral vascular flow, a characteristic feature of a parathyroid adenoma.
Based on these findings, the patient was classified as a prime candidate for a parathyroidectomy. However, the trajectory of his treatment was abruptly altered during a preoperative cardiac evaluation. The assessment revealed that the patient suffered from severe multivessel coronary artery disease, rendering immediate surgery too risky. He instead underwent percutaneous coronary intervention with stent placement, which necessitated a six-month regimen of dual antiplatelet therapy.
The Role of Cinacalcet as a Bridging Therapy
Because the patient’s hypercalcemia was symptomatic and required management during the six-month delay, the clinical team initiated treatment with cinacalcet. Cinacalcet is a calcimimetic agent that works by increasing the sensitivity of calcium-sensing receptors (CaSR) on the surface of parathyroid cells. By mimicking the action of calcium, the drug signals the parathyroid glands to reduce the secretion of PTH, thereby lowering serum calcium levels.
The U.S. Food and Drug Administration (FDA) has approved cinacalcet for the treatment of severe hypercalcemia in patients with PHPT who are unable to undergo surgery. In this specific case, the medication was intended solely as a "bridge therapy" to stabilize the patient until his cardiac status allowed for a parathyroidectomy. The dosage began at 30 mg daily and was eventually titrated to 30 mg twice daily.
The patient’s response to the medication was more dramatic than anticipated. After six months, he returned to the clinic reporting new-onset paresthesias (tingling sensations), a common symptom of low calcium. Laboratory tests confirmed that his serum calcium had plummeted to 6.8 mg/dL and his PTH had dropped to 14 pg/mL—levels indicative of frank hypocalcemia. The clinical team immediately discontinued the cinacalcet and replaced it with oral calcium supplementation. Within one month, the patient’s biochemistry had stabilized, with a calcium level of 9.1 mg/dL and a PTH of 44 pg/mL, both within the normal reference range.
The Vanishing Adenoma: A Deviation from Standard Medical Knowledge
The most startling discovery occurred during a follow-up ultrasound. Typically, cinacalcet is understood to manage the symptoms of PHPT without affecting the underlying tumor size. However, the repeat imaging showed that the 2.3 × 1.7 × 3.0 cm mass had regressed significantly to 1.4 × 1.0 × 1.1 cm, representing a volume reduction of more than 50%.
Dr. Sara Ramadan noted the rarity of this occurrence, stating that cinacalcet’s known mechanism of action does not involve the shrinkage of a parathyroid adenoma. Usually, when the drug is discontinued, patients experience a "rebound" effect where calcium and PTH levels return to their previous high levels. In this instance, the patient remained eucalcemic (having normal calcium levels) without further medication. At a one-year follow-up, his calcium remained stable at 9.8 mg/dL. Remarkably, nearly three years after the initial treatment, his calcium levels were still within normal limits at 8.9 mg/dL on vitamin D supplementation alone.
Scientific Analysis: Apoptosis vs. Apoplexy
The research team explored two primary hypotheses to explain this rare clinical outcome: parathyroid apoplexy and apoptotic involution.
Parathyroid apoplexy is a phenomenon involving the spontaneous hemorrhagic infarction of a parathyroid adenoma. This event causes the sudden death of the tumor tissue (necrosis), leading to a rapid normalization of biochemical markers. However, apoplexy is usually accompanied by acute clinical symptoms such as sudden neck pain, swelling, or difficulty swallowing (dysphagia). Given that the patient experienced a gradual decline in calcium levels without acute pain, and that ultrasound showed preserved texture in the remaining mass rather than signs of hemorrhage, the team deemed apoplexy unlikely.
The second and more likely theory is apoptotic involution. This hypothesis suggests that the upregulation of calcium-sensing receptors (CaSR) caused by cinacalcet may restore normal signaling pathways that eventually trigger programmed cell death (apoptosis) within the adenomatous tissue. While some in vitro and animal studies have suggested that high doses of calcimimetics could induce apoptosis, this effect has rarely been documented in human clinical cases. Dr. Ramadan suggested that the clinical picture pointed toward a slow, apoptotic process, though she noted that definitive proof would require a biopsy to examine the cellular pathology—a procedure the patient was hesitant to undergo.
Ethical Considerations and the Future of PHPT Research
The findings of this case raise important questions regarding the future of medical management for PHPT. If cinacalcet can occasionally lead to permanent remission, could it eventually serve as an alternative to surgery for a broader range of patients?
Currently, the answer remains cautious. Surgery has a cure rate exceeding 95% and is considered highly safe. Dr. Ramadan emphasized the ethical difficulty of conducting prospective trials to test cinacalcet as a primary curative agent. Randomizing patients to medical therapy when a highly effective surgical cure exists would be difficult to justify. Furthermore, the rarity of such remissions suggests that they may only occur in a very specific subset of patients, necessitating large-scale, long-term studies that are currently impractical to execute.
Addressing Health Disparities and Recurrence
Dr. Ramadan’s work at Boston Medical Center, a major safety-net hospital, has also influenced her focus on health disparities within the field of endocrinology. Research has shown that African American women are at a higher risk for PHPT and often present with more severe biochemical symptoms. These disparities are often exacerbated by differences in healthcare access and metabolic factors.
As Dr. Ramadan moves forward in her career, her research interests have shifted toward recurrent primary hyperparathyroidism. These cases are particularly complex because patients have already undergone surgery, resulting in altered neck anatomy and making subsequent imaging and surgical decisions more difficult. Understanding why certain tumors recur and identifying the biological markers that predict medical responsiveness are key goals for her future work.
The Impact of Professional Societies on Early-Career Physicians
The publication of this case study marks a significant milestone for Dr. Ramadan, who is currently an early-career member of the Endocrine Society. She credits the society’s Early Career Membership program with providing the mentorship and resources necessary to navigate the transition from residency to fellowship.
Through the Endocrine Society’s annual ENDO conference, Dr. Ramadan was able to engage with experienced clinicians and observe real-time problem-solving for complex endocrine cases. She highlighted that exposure to new diagnostic technologies and the ability to network with program directors from across the country have been instrumental in her professional development. As she prepares to relocate to Seattle for her fellowship after completing her residency at Boston Medical Center-Brighton, she emphasizes the importance of these professional connections in defining a research niche.
Conclusion: A Paradigm Shift in Endocrine Care?
While the case of the "vanishing adenoma" may currently be an outlier, it serves as a critical reminder of the complexities of endocrine physiology. The unanticipated remission documented by Dr. Ramadan and Dr. Haddady provides a foundation for future investigation into the non-surgical management of parathyroid disorders. As the medical community continues to refine its understanding of the calcium-sensing receptor and its role in tumor growth, the possibility of medical "cures" for PHPT may move from a clinical rarity to a viable area of pharmacological research. For now, the study stands as a testament to the importance of meticulous clinical observation and the potential for unexpected outcomes to drive the next generation of medical inquiry.
